Clinical and economic impact of vagus nerve stimulation therapy in patients with drug-resistant epilepsy

  title={Clinical and economic impact of vagus nerve stimulation therapy in patients with drug-resistant epilepsy},
  author={Sandra Helmers and Mei Sheng Duh and Annie Gu{\'e}rin and Sujata P Sarda and Thomas M. Samuelson and Mark T. Bunker and Bryan D. Olin and Stanley D. Jackson and Edward Faught},
  journal={Epilepsy \& Behavior},

Figures and Tables from this paper

Clinical outcomes, quality of life, and costs associated with implantation of vagus nerve stimulation therapy in pediatric patients with drug-resistant epilepsy.

  • S. HelmersM. Duh E. Faught
  • Medicine
    European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
  • 2012

Expected Budget Impact and Health Outcomes of Expanded Use of Vagus Nerve Stimulation Therapy for Drug-Resistant Epilepsy

VNS is a proven intervention that offers a long-term solution for patients with drug-resistant epilepsy with DRE by reducing seizure frequency, which leads to lower resource utilization and lower costs.

Efficacy of Vagus Nerve Stimulation in Patients with Drug Resistant Epilepsy

Given the potential for cognitive, behavioural improvement with or without improved seizure control, VNS may be considered in the course of treatment of refractory epilepsy.

Health Technology Assessment Report on Vagus Nerve Stimulation in Drug-Resistant Epilepsy

Assessment of the clinical, organizational, financial, and economic impact of VNS therapy in drug-resistant epilepsies and the congruity between costs incurred and health service reimbursement indicates VNS as an effective treatment with a potential positive impact on social aspects and on quality of life.

An economic evaluation of vagus nerve stimulation as an adjunctive treatment to anti-seizure medications for the treatment of drug-resistant epilepsy in England

An economic model showed that adding VNS to ASMs can be a cost-effective way to treat DRE in today's NHS in England, and found that the amount of resource use per epilepsy-related health state was a key driver of the cost component.

Economic and clinical evaluation of vagus nerve stimulation therapy

The study objective was to analyze the effect of VNS on clinical effects improvement and therapy cost reduction in patients with DRE over a 2‐year follow-up period, and compare average costs of V NS treatment of patients withDRE in selected countries, taking into account the purchasing power parity.

Vagus nerve stimulation (VNS) therapy update




Vagus nerve stimulation therapy for partial-onset seizures

Vagus nerve stimulation is an effective and safe adjunctive treatment for patients with refractory partial-onset seizures and represents the advent of a new, nonpharmacologic treatment for epilepsy.

Vagus nerve stimulation for refractory epilepsy: a Belgian multicenter study.

  • V. De HerdtP. Boon K. Vonck
  • Medicine
    European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
  • 2007

Vagus nerve stimulation: Longitudinal follow-up of patients treated for 5 years

Analysis of direct hospital costs before and 18 months after treatment with vagus nerve stimulation therapy in 43 patients

VNS therapy resulted in annual reductions of approximately $3000 in unplanned hospital costs per study patient, direct savings sustained over the battery life of the VNS therapy system can equal or exceed the purchase price of the device.

A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures

VNS may be an effective alternative treatment for patients who have failed antiepileptic drug therapy and are not optimal candidates for epilepsy surgery, and largely limited to a transient hoarseness occurring during the stimulation train.

Direct medical costs for partial refractory epilepsy in Mexico.

A randomized, controlled trial of surgery for temporal-lobe epilepsy.

In temporal-lobe epilepsy, surgery is superior to prolonged medical therapy, and Randomized trials of surgery for epilepsy are feasible and appear to yield precise estimates of treatment effects.

Early identification of refractory epilepsy.

Patients who have many seizures before therapy or who have an inadequate response to initial treatment with antiepileptic drugs are likely to have refractory epilepsy.